CAMRF (Camurus AB) Operating Margin %: 31.59% (As of Mar. 2026)


CAMRF Camurus AB CAMRF
79 GF Score
Price $54.00
GF Value $83.14
Valuation Significantly Undervalued
! 1 Warning Sign
View Full Analysis

What is Camurus AB Operating Margin %?

Camurus AB CAMRF -3.57% 79 Operating Margin % is 31.59% as of Mar. 2026. GuruFocus rates CAMRF with a GF Score™ of 79/100 and a GF Value™ of $83.14 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 945 Biotechnology companies, Camurus AB ranks better than 94.71% on this metric.

Operating Margin % is calculated as Operating Income divided by its Revenue. Camurus AB's Operating Income for the three months ended in Mar. 2026 was $18.1 Mil. Camurus AB's Revenue for the three months ended in Mar. 2026 was $57.2 Mil. Therefore, Camurus AB's Operating Margin % for the quarter that ended in Mar. 2026 was 31.59%.

The historical rank and industry rank for Camurus AB's Operating Margin % or its related term are showing as below:

CAMRF' s Operating Margin % Range Over the Past 10 Years
Min: -583.48   Med: -40.1   Max: 38.58
Current: 35.87


CAMRF's Operating Margin % is ranked better than
94.71% of 945 companies
in the Biotechnology industry
Industry Median: -86.77 vs CAMRF: 35.87

Camurus AB's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

Camurus AB's Operating Income for the three months ended in Mar. 2026 was $18.1 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2026 was $85.4 Mil.


Camurus AB  (OTCPK:CAMRF) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Camurus AB Operating Margin % Related Terms


Camurus AB Operating Margin % Historical Data

* Premium members only.

The historical data trend for Camurus AB's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Camurus AB Operating Margin % Chart

Camurus AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Operating Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -18.71 7.45 31.07 24.83 38.58

Camurus AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 42.78 43.23 40.60 24.28 31.59

CAMRF vs VRTX, REGN, ALNY: Operating Margin % Comparison

For the Biotechnology subindustry, Camurus AB's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Camurus AB Operating Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Camurus AB's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Camurus AB's Operating Margin % falls into.


CAMRF
79GF Score
Camurus AB CAMRF
Operating Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Camurus AB Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Camurus AB's Operating Margin % for the fiscal year that ended in Dec. 2025 is calculated as

Operating Margin %=Operating Income (A: Dec. 2025 ) / Revenue (A: Dec. 2025 )
=94.032 / 243.759
=38.58 %

Camurus AB's Operating Margin % for the quarter that ended in Mar. 2026 is calculated as

Operating Margin %=Operating Income (Q: Mar. 2026 ) / Revenue (Q: Mar. 2026 )
=18.074 / 57.217
=31.59 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Operating Margin % →
What does a Operating Margin % of 31.59% mean?
Camurus AB (CAMRF) has a Operating Margin % of 31.59% as of Mar. 2026. Operating margin is the ratio of total operating income to net sales. View historical data on Camurus AB and its competitors. According to the industry distribution chart, Camurus AB ranks #50 out of 945 companies in the Biotechnology industry, placing it in the top 5.3%.
Is Camurus AB's Operating Margin % too high?
Camurus AB's current Operating Margin % is 31.59%. Based on the distribution chart, Camurus AB ranks #50 out of 945 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Camurus AB has a GF Score™ of 79/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Camurus AB's Operating Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Camurus AB ranks #50 out of 945 companies for Operating Margin %. This places Camurus AB in the top 5% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Biotechnology company?
A good Operating Margin % depends on the Biotechnology industry context. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Camurus AB and its competitors. Camurus AB's current Operating Margin % is 31.59%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Camurus AB stock overvalued right now?
Based on GuruFocus' analysis, Camurus AB (CAMRF) is currently considered Significantly Undervalued. The stock's GF Value™ is $83.14, compared to a current price of $54.00 — trading 35% below its estimated fair value. The current Operating Margin % is 31.59%. Camurus AB's overall GF Score™ is 79/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Camurus AB (CAMRF), the current Operating Margin % is 31.59% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Camurus AB (CAMRF) Overvalued in 2026?

Based on GuruFocus' analysis, Camurus AB stock appears to be undervalued. The current stock price of $54.00 is trading 35% below its estimated GF Value™ of $83.14. GuruFocus considers Camurus AB to be Significantly Undervalued.

Key valuation signals for CAMRF:

  • Operating Margin %: 31.59%
  • GF Value™: $83.14 vs. price of $54.00 (35% below fair value)
  • GF Score™: 79/100 with 1 warning sign

No single metric tells the full story. See the CAMRF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Camurus AB Business Description

Address Rydbergs torg 4, Lund, SWE, SE-224 84
Camurus AB is a science-led biopharmaceutical company focused on developing and commercializing long-acting medicines for the treatment of severe and chronic diseases. It has two approved products, including treatments for opioid dependence, and a development pipeline supported by its FluidCrystal technology. Its clinical pipeline includes product candidates for conditions such as pain, cancer, endocrine, and metabolic diseases, developed in-house and in collaboration with international pharmaceutical companies. Its pipeline programs include CAM2029 for acromegaly, gastroenteropancreatic neuroendocrine tumors, and polycystic liver disease; CAM2038 for chronic pain; CAM4072 for genetic obesity disorders; CAM2043 for Raynaud's phenomenon; CAM4071 for endocrine disorders, among others.
79GF Score

Get the complete analysis for CAMRF

Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$54.00
Price
$83.14
GF Value